Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$190.90 USD
+0.18 (0.09%)
Updated Oct 13, 2025 03:59 PM ET
After-Market: $190.73 -0.17 (-0.09%) 6:24 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Johnson & Johnson has a PEG ratio of 2.60 compared to the Large Cap Pharmaceuticals industry's PEG ratio of 1.58.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
JNJ 190.90 +0.18(0.09%)
Will JNJ be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JNJ
Markets Rebound Nicely Ahead of Q3 Earnings Season
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is J&J's MedTech Segment Set for Another Quarter of Growth?
3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
Other News for JNJ
Protagonist Therapeutics falls amid a report J&J deal price may be lower
Johnson & Johnson (JNJ) Q3 Earnings Preview: MedTech Focused Performance
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch
Johnson & Johnson Stock (JNJ) Falters Ahead of Earnings Release as Cancer Therapy Gets Warning Label
Johnson & Johnson Stock (JNJ) Falters Ahead of Earnings as Cancer Therapy Gets Warning Label